The latest updates on Ozempic, Mounjaro, Wegovy and GLP-1 treatments
Tirzepatide often produces steeper weight loss early on. Here's what clinical trials reveal about that initial drop and what to expect as treatment continues.
An oral GLP-1 option from Eli Lilly could change the game for UK patients. Here's what we know about Foundayo and its potential UK availability.
Considering switching from Ozempic to Mounjaro? Learn the key differences in how they work, dosing schedules, effectiveness, and what to discuss with your doctor.
Research suggests GLP-1 medications may improve fertility outcomes in women with obesity and PCOS. Here's what the science says.
The high demand for tirzepatide has created a lucrative black market at the border. Learn why patients risk smuggling and what dangers they face.
Restaurant dining presents unique challenges for patients on GLP-1 weight loss medications due to their appetite-suppressing effects and food preference changes.
Science shows that sleep deprivation disrupts the same hunger hormones that Ozempic and Mounjaro target. Here's what happens inside your body when you don't sleep enough on GLP-1 therapy.
Many patients wonder if they can get back on track after stopping semaglutide. Here's what the research and doctors say about restarting GLP-1 treatment.
Brazil now has its own semaglutide injection made on national soil. Learn how Ozivy works, what makes it different from existing options, and what it could mean for access to GLP-1 therapies in the country.
Brazil's ANVISA just approved a second generic semaglutide, opening the door to more competition and potentially lower prices for GLP-1 medications. Here's what to expect.
Answer a few quick questions and get tailored guidance for your treatment.
or download the app
